TY - JOUR
T1 - Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks
AU - Kehrloesser, Sebastian
AU - Oberst, Simon
AU - Westerhuis, Willien
AU - Wendler, Astrid
AU - Wind, Anke
AU - Blaauwgeers, Harriët
AU - Burrion, Jean Benoit
AU - Nagy, Péter
AU - Saeter, Gunnar
AU - Gustafsson, Eva
AU - De Paoli, Paolo
AU - Lovey, József
AU - Lombardo, Claudio
AU - Philip, Thierry
AU - de Valeriola, Dominique
AU - Docter, Marjet
AU - Boomsma, Femke
AU - Saghatchian, Mahasti
AU - Svoboda, Marek
AU - Philip, Irene
AU - Monetti, Francesco
AU - Hummel, Henk
AU - McVie, Gordon
AU - Otter, Renée
AU - van Harten, Wim
N1 - Funding Information:
SK, SO and AW received funding from the Organisation of European Cancer Institutes for this work. WvH receives a nonrestricted grant from Novartis, a nonrestricted grant from Agendia BV and a nonrestricted grant from Intuitive Surgical. PN and JL acknowledge financial support from the Hungarian Thematic Excellence Programme (TKP2020‐NKA‐26). All remaining authors have declared no conflicts of interest.
Publisher Copyright:
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
PY - 2021/5
Y1 - 2021/5
N2 - There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe’s Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes’ Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.
AB - There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and Europe’s Beating Cancer Plan) is currently moving towards a mission-oriented approach addressing these inequalities. In this study, we used the quantitative and qualitative data of the Organisation of European Cancer Institutes’ Accreditation and Designation Programme, relating to 40 large European cancer centres, to describe their current compliance with quality standards, to identify the hallmarks common to all centres and to show the distinctive features of Comprehensive Cancer Centres. All Comprehensive Cancer Centres and Cancer Centres accredited by the Organisation of European Cancer Institutes show good compliance with quality standards related to care, multidisciplinarity and patient centredness. However, Comprehensive Cancer Centres on average showed significantly better scores on indicators related to the volume, quality and integration of translational research, such as high-impact publications, clinical trial activity (especially in phase I and phase IIa trials) and filing more patents as early indicators of innovation. However, irrespective of their size, centres show significant variability regarding effective governance when functioning as entities within larger hospitals.
KW - accreditation
KW - clinical trials
KW - comprehensive cancer center
KW - multidisciplinarity
KW - quality standard
KW - translational research
UR - http://www.scopus.com/inward/record.url?scp=85103396826&partnerID=8YFLogxK
U2 - 10.1002/1878-0261.12950
DO - 10.1002/1878-0261.12950
M3 - Article
C2 - 33734563
AN - SCOPUS:85103396826
VL - 15
SP - 1277
EP - 1288
JO - Molecular oncology
JF - Molecular oncology
SN - 1574-7891
IS - 5
ER -